<DOC>
	<DOCNO>NCT02657876</DOCNO>
	<brief_summary>This study design prospective , multicenter , open-label trial focus assess safety tolerability ExpressGraft-C9T1 skin tissue treatment diabetic foot ulcer ( DFU ) . Because focus safety rather efficacy , standard care comparator include first-in-human study . Targeted enrollment study 6 subject confirm diagnosis diabetes foot ulcer . Subjects receive single application ExpressGraft-C9T1 skin tissue single identify study DFU follow 6-10 day run-in period . Any subject require additional treatment receive protocol-defined dressing study session 7 necessary . Enrollment occur minimum one week subject .</brief_summary>
	<brief_title>ExpressGraft-C9T1 Skin Tissue Treatment Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Men woman 18 80 year age , inclusive 2 . Female subject childbearing potential must agree practice birth control duration study 3 . Documented Type 1 Type 2 diabetes mellitus 4 . HgB A1c ≤ 10.0 % 5 . Ankle : brachial blood pressure index ( ABI ) 0.7 1.3 Toe brachial index ( TBI ) ≥ 0.5 patient noncompressible ankle vessel define ABI ≥ 1.3 Transcutaneous pressure ( TCPO2 ) ≥ 40 ABI TBI measure 6 . Stable medication 2 week prior day 0 Sliding scale insulin permit Select antimicrobial therapy use need 7 . Capable willing attend schedule visit comply study procedure 8 . Signed informed consent study enrollment 9 . Fullthickness ulcer foot 1.0 cm2 10.0 cm2 screen debridement clinical sign symptom infection . Fullthickness define penetrate dermis , extend beyond subcutaneous tissue . 10 . Study ulcer present least 4 week 1 . Pregnant nursing woman prisoners 2 . Abnormal laboratory value ( ) routine blood work Clinical Investigator deem would subject 's best interest participate 3 . Osteomyelitis study ulcer foot last 30 day 4 . Grade 3 4 low extremity edema 5 . Unable tolerate offload 6 . Charcot 's foot 7 . History malignancy previous 5 year , except basal cell carcinoma treat local excision longer present 8 . Patients unstable chronic renal disease require dialysis 9 . Gangrene part study ulcer foot 10 . Patients history amputation relate underlying chronic disease 11 . Patients history poor compliance 12 . Patients baseline PRA ≥ 20 % 13 . Oral parenternal corticosteriods , immunosuppressant , radiation therapy chemotherapy within 30 day prior study enrollment 14 . Use investigational product within precede 60 day 15 . Signs symptoms clinical infection study ulcer site include limited purulence and/or presence sinus tracts 16 . Study ulcer require antimicrobial therapy screen visit due clinical suspicion infection 17 . Treatment study ulcer Regranex® hyperbaric oxygen within precede 30 day 18 . Previous treatment study ulcer cellbased therapy 19 . Change wound size ( increase/decrease ) great 30 % screen visit study day 0 20 . Other ulcer within 3 cm study ulcer 21 . Ulcers tendon , muscle , bone exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>